Donate
  • About Us
    • Our Vision, Mission & Values
    • About Clyde
    • Our MJFF partnership
    • Our Board
    • Our Patron
    • Our Ambassadors
    • Our Team
    • In The Media
    • Annual Report
  • Research
    • Our MJFF Partnership
    • Our Research Projects
    • Catalyst Programme velocity (CPv)
    • Research Trials
    • How We Fund
    • For Researchers
    • Research News
    • Research Forums
  • News
  • About PD
    • Symptoms of Parkinson’s
    • Treatments for Parkinson’s
    • Living with Parkinson’s
    • Sharing Your Diagnosis
    • Young Onset Parkinson’s
    • Genetics
    • Caregiver Information
    • Parkinson’s Stories
  • Trials
  • Contact
  • Get Involved
    • Fundraise for Parkinson’s
    • In Memory Donations
    • Bequest to Parkinson’s
    • Corporate Support
  • Donate
  • About Us
    • Our Vision, Mission & Values
    • About Clyde
    • Our MJFF partnership
    • Our Board
    • Our Patron
    • Our Ambassadors
    • Our Team
    • In The Media
    • Annual Report
  • Research
    • Our MJFF Partnership
    • Our Research Projects
    • Catalyst Programme velocity (CPv)
    • Research Trials
    • How We Fund
    • For Researchers
    • Research News
    • Research Forums
  • News
  • About PD
    • Symptoms of Parkinson’s
    • Treatments for Parkinson’s
    • Living with Parkinson’s
    • Sharing Your Diagnosis
    • Young Onset Parkinson’s
    • Genetics
    • Caregiver Information
    • Parkinson’s Stories
  • Trials
  • Contact
  • Get Involved
    • Fundraise for Parkinson’s
    • In Memory Donations
    • Bequest to Parkinson’s
    • Corporate Support
  • Donate
Studying the genetic link of Parkinson’s could lead to new treatments for everyone
Monday, 31st October 2016

The genetics of Parkinson’s is complex, but each new study helps us piece together a greater understanding of how key genes, such as LRRK2, contribute to Parkinson’s disease (PD).

Carrying a LRRK2  mutation increases the risk of PD, but the age at which the disease appears (if it does; not all with the mutation develop PD) differs greatly. Recently reported results from a Michael J. Fox Foundation-funded study may help explain why.

Investigators from the University of British Columbia reporting in The Lancet Neurology identified a change in a gene modifier called Dynamin-3 (or DNM3)  that, when present in people who carry a LRRK2 mutation, accelerated the age of PD onset by about 12 years.

These findings provide important insights into the heterogeneity of PD, even in those known to be carriers of the same genetic mutation. Much like adding different spices to a dish can add or detract from the overall flavor, changes in these so-called modifying genes may influence the impact of other genes in small, but noticeable, ways. Results from this study suggest that targeting genetic modifiers could be neuroprotective for individuals who carry LRRK2  mutations and could delay onset of the disease.

The Foundation is currently funding several investigators as part of a LRRK2  Modifier Consortium to identify additional genetic modifiers of LRRK2  and further explore the role of LRRK2  modifiers on age of PD onset. In addition, MJFF’s landmark biomarkers study, the Parkinson’s Progression Markers Initiative (PPMI), is currently enrolling people with LRRK2  mutations to learn more about this subset of Parkinson’s. And MJFF has organized the LRRK2 Cohort Consortium to identify and learn from people who carry LRRK2  mutations.

Although genetic mutations affect a relatively small number of individuals with Parkinson’s, studying genetics can help researchers learn more about the biology of Parkinson’s, which could lead to new therapies that could help all individuals PD.

Shake It Up is excited to be funding several projects into LRRK2.  Find out more about these projects and how you can get involved by donating to Parkinson’s research

SHARE THIS ARTICLE

Related Post

Gene Therapy for Parkinson’s
A ‘Milestone Moment’ for Parkinson’s: LRRK2 drug moves to next stage
My Grandfather, My Father – Am I Next?
Shake It Up Foundation
ABN: 65 270 391 304
Contact Us
1300 361 803
enquiries@shakeitup.org.au
ADDRESS
To mail a cheque:
Shake it up Australia Foundation:
PO Box 710, Spit Junction NSW 2088
LINKS
  • About Us
  • Register Clinical Trials
  • Getting Involved
  • Our Research
  • About Parkinson’s
  • Contact Us
OUR COMMUNITY
ACNC Registered Charity
FAQS | PRIVACY POLICY | Website by
Copyright © 2023 Shake It Up Australia Foundation. All rights reserved